New study led by our rockstar PhD student, Sophie Poznanski, recently published in the Journal for ImmunoTherapy of Cancer shows that expanded NK cells from lung cancer patients are highly potent against PD1+ and PD1- patient derived tumors. Impressively, the high IFN-gamma produced by expanded NK cells upregulated PD1-expression on PD1-negative tumors, suggesting that combination therapy of expanded NK cells and PD1 checkpoint blockade therapy can be used as a powerful treatment against lung cancer.
The study was also highlighted by McMaster University here!
Thank you to everyone in the lab who contributed to this exciting advancement in lung cancer immunotherapy!
